MCK earnings analysis
What we found in MCK's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
McKesson Corporation's FY 2026 10-K report highlights a strategic shift towards operational efficiencies and expanded service offerings, reflected in a 12% revenue increase year-over-year to $403.43 billion, coupled with a 49% increase in diluted EPS to $38.38. The company is transitioning into a more focused structure with planned separations of certain segments, amidst ongoing legal challenges and market competitiveness.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Impressive Revenue Growth
- Total revenues increased 12% to $403.43 billion for FY 2026, driven by the North American Pharmaceutical segment.
- Significant EPS Growth
- Diluted EPS rose 49% from $25.72 in FY 2025 to $38.38 in FY 2026.
- Strong Cash Flow Generation
- Free cash flow was $1.12 billion for Q3 FY 2026, supporting robust operational funding.
- Successful Acquisitions
- Acquired a controlling interest in PRISM Vision for $875M, enhancing oncology services.
- Increased Shareholder Returns
- Returned $5.1 billion to shareholders via $4.8 billion in stock buybacks and $381 million in dividends.
- Strategic Segment Reporting
- Transitioned to 4 reportable segments to streamline operations and improve focus.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Litigation Risks
- Ongoing opioid-related litigation could result in significant financial impacts; estimated accrued liability at $5.7 billion.
- Market Volatility Exposure
- Rapid fluctuations in pharmaceuticals market pricing and reimbursement policies can adversely affect revenues.
- Operational Execution Risks
- Transitioning business structure and focus on operational efficiency may disrupt existing operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $38.38
- Gross margin
- 3.61%
- Operating margin
- 1.54%
- Segment
- North American Pharmaceutical
- Segment
- Oncology & Multispecialty
- Segment
- Prescription Technology Solutions
- Segment
- Medical-Surgical Solutions
What they said about what is next.
Fiscal 2027 outlook deferred to earnings press release / call.
The filing reads better than the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing MCK makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever